Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca
Synopsis
The company expects the transaction, which was announced in February, to close in the third quarter of 2025.
FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong Kong) to AstraZeneca (AZN).
FibroGen had announced the sale of its China unit to AstraZeneca for about $160 million in February. The closing of the transaction is now expected in the third quarter of 2025, the company said.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.